Ypsomed Holding AG Logo

Ypsomed Holding AG

YPSN.SW

(2.2)
Stock Price

427,50 CHF

6.91% ROA

12.75% ROE

95.5x PER

Market Cap.

4.163.958.585,00 CHF

29.67% DER

0.21% Yield

14.24% NPM

Ypsomed Holding AG Stock Analysis

Ypsomed Holding AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ypsomed Holding AG Fundamental Stock Analysis
# Analysis Rating
1 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

2 ROE

The stock's ROE falls within an average range (5.86%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (4.08%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 DER

The stock has a reasonable amount of debt compared to its ownership (68%), suggesting a balanced financial position and a moderate level of risk.

5 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

6 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

7 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

8 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (10.412), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

9 PBV

The stock's high Price-to-Book Value (P/BV) ratio (8.85x) suggests it's overvalued, potentially making it an expensive investment.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Ypsomed Holding AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ypsomed Holding AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Ypsomed Holding AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ypsomed Holding AG Revenue
Year Revenue Growth
2001 100.613.000
2002 137.187.000 26.66%
2003 185.365.000 25.99%
2004 241.823.000 23.35%
2005 310.588.000 22.14%
2006 277.450.000 -11.94%
2007 287.468.000 3.48%
2008 272.580.000 -5.46%
2009 254.014.000 -7.31%
2010 242.461.000 -4.76%
2011 248.593.000 2.47%
2012 244.565.000 -1.65%
2013 276.257.000 11.47%
2014 306.632.000 9.91%
2015 336.922.000 8.99%
2016 389.555.000 13.51%
2017 466.119.000 16.43%
2018 453.765.000 -2.72%
2019 393.866.000 -15.21%
2020 393.866.000 0%
2020 403.656.000 2.43%
2021 464.841.000 13.16%
2022 506.432.000 8.21%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ypsomed Holding AG Research and Development Expenses
Year Research and Development Expenses Growth
2001 -795.000
2002 -4.559.000 82.56%
2003 -6.397.000 28.73%
2004 40.581.000 115.76%
2005 17.206.000 -135.85%
2006 21.909.000 21.47%
2007 43.235.000 49.33%
2008 10.463.000 -313.22%
2009 7.324.000 -42.86%
2010 9.247.000 20.8%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 56.838.000 100%
2019 18.247.000 -211.49%
2020 0 0%
2020 16.788.000 100%
2021 21.954.000 23.53%
2022 57.906.000 62.09%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ypsomed Holding AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 18.175.000
2002 23.507.000 22.68%
2003 33.407.000 29.63%
2004 35.045.000 4.67%
2005 887.000 -3850.96%
2006 -2.830.000 131.34%
2007 46.275.000 106.12%
2008 44.244.000 -4.59%
2009 49.910.000 11.35%
2010 50.367.000 0.91%
2011 12.754.000 -294.91%
2012 12.752.000 -0.02%
2013 13.884.000 8.15%
2014 15.530.000 10.6%
2015 15.782.000 1.6%
2016 18.154.000 13.07%
2017 20.720.000 12.38%
2018 24.070.000 13.92%
2019 21.981.000 -9.5%
2020 21.981.000 0%
2020 21.095.000 -4.2%
2021 23.029.000 8.4%
2022 26.176.000 12.02%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ypsomed Holding AG EBITDA
Year EBITDA Growth
2001 18.662.000
2002 27.648.000 32.5%
2003 47.314.000 41.56%
2004 43.072.000 -9.85%
2005 89.879.000 52.08%
2006 28.580.000 -214.48%
2007 55.597.000 48.59%
2008 59.569.000 6.67%
2009 41.937.000 -42.04%
2010 35.357.000 -18.61%
2011 31.904.000 -10.82%
2012 30.461.000 -4.74%
2013 39.690.000 23.25%
2014 52.390.000 24.24%
2015 71.244.000 26.46%
2016 84.244.000 15.43%
2017 96.835.000 13%
2018 116.677.000 17.01%
2019 60.543.000 -92.72%
2020 61.036.000 0.81%
2020 60.830.000 -0.34%
2021 95.932.000 36.59%
2022 61.340.000 -56.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ypsomed Holding AG Gross Profit
Year Gross Profit Growth
2001 25.659.000
2002 42.270.000 39.3%
2003 71.725.000 41.07%
2004 96.887.000 25.97%
2005 119.213.000 18.73%
2006 64.239.000 -85.58%
2007 90.197.000 28.78%
2008 84.001.000 -7.38%
2009 66.446.000 -26.42%
2010 66.724.000 0.42%
2011 56.372.000 -18.36%
2012 57.075.000 1.23%
2013 70.526.000 19.07%
2014 85.850.000 17.85%
2015 103.187.000 16.8%
2016 125.479.000 17.77%
2017 139.826.000 10.26%
2018 156.414.000 10.61%
2019 90.576.000 -72.69%
2020 90.576.000 0%
2020 94.828.000 4.48%
2021 113.817.000 16.68%
2022 150.288.000 24.27%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ypsomed Holding AG Net Profit
Year Net Profit Growth
2001 5.776.000
2002 12.061.000 52.11%
2003 11.590.000 -4.06%
2004 39.195.000 70.43%
2005 55.648.000 29.57%
2006 2.742.000 -1929.47%
2007 26.583.000 89.69%
2008 26.166.000 -1.59%
2009 9.425.000 -177.62%
2010 5.206.000 -81.04%
2011 8.500.000 38.75%
2012 1.646.000 -416.4%
2013 13.608.000 87.9%
2014 19.395.000 29.84%
2015 35.812.000 45.84%
2016 46.247.000 22.56%
2017 52.060.000 11.17%
2018 60.136.000 13.43%
2019 11.452.000 -425.11%
2020 11.452.000 0%
2020 5.811.000 -97.07%
2021 23.105.000 74.85%
2022 71.672.000 67.76%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ypsomed Holding AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 1
2002 4.811 100%
2003 1 -480900%
2004 3 66.67%
2005 5 25%
2006 0 0%
2007 2 100%
2008 2 0%
2009 1 0%
2010 0 0%
2011 1 0%
2012 0 0%
2013 1 100%
2014 2 0%
2015 3 50%
2016 4 33.33%
2017 4 25%
2018 5 0%
2019 1 0%
2020 1 0%
2020 0 0%
2021 2 100%
2022 5 80%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ypsomed Holding AG Free Cashflow
Year Free Cashflow Growth
2001 -12.245.000
2002 -2.521.000 -385.72%
2003 -11.473.000 78.03%
2004 22.303.000 151.44%
2005 15.818.000 -41%
2006 7.561.000 -109.21%
2007 16.807.000 55.01%
2008 48.404.000 65.28%
2009 -23.901.000 302.52%
2010 3.280.000 828.69%
2011 15.130.000 78.32%
2012 -11.243.000 234.57%
2013 10.569.000 206.38%
2014 10.887.000 2.92%
2015 40.488.000 73.11%
2016 36.902.000 -9.72%
2017 -13.816.000 367.1%
2018 -69.194.000 80.03%
2019 -69.642.000 0.64%
2020 -40.753.000 -70.89%
2021 -41.724.000 2.33%
2022 7.962.000 624.04%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ypsomed Holding AG Operating Cashflow
Year Operating Cashflow Growth
2001 6.496.000
2002 20.398.000 68.15%
2003 26.535.000 23.13%
2004 94.775.000 72%
2005 46.365.000 -104.41%
2006 30.960.000 -49.76%
2007 70.155.000 55.87%
2008 48.404.000 -44.94%
2009 22.480.000 -115.32%
2010 29.504.000 23.81%
2011 31.055.000 4.99%
2012 15.168.000 -104.74%
2013 41.206.000 63.19%
2014 41.381.000 0.42%
2015 76.687.000 46.04%
2016 75.064.000 -2.16%
2017 53.269.000 -40.91%
2018 59.859.000 11.01%
2019 49.089.000 -21.94%
2020 85.828.000 42.81%
2021 85.706.000 -0.14%
2022 29.894.500 -186.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ypsomed Holding AG Capital Expenditure
Year Capital Expenditure Growth
2001 18.741.000
2002 22.919.000 18.23%
2003 38.008.000 39.7%
2004 72.472.000 47.55%
2005 30.547.000 -137.25%
2006 23.399.000 -30.55%
2007 53.348.000 56.14%
2008 0 0%
2009 46.381.000 100%
2010 26.224.000 -76.86%
2011 15.925.000 -64.67%
2012 26.411.000 39.7%
2013 30.637.000 13.79%
2014 30.494.000 -0.47%
2015 36.199.000 15.76%
2016 38.162.000 5.14%
2017 67.085.000 43.11%
2018 129.053.000 48.02%
2019 118.731.000 -8.69%
2020 126.581.000 6.2%
2021 127.430.000 0.67%
2022 21.932.500 -481.01%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ypsomed Holding AG Equity
Year Equity Growth
2001 95.578.000
2002 111.683.000 14.42%
2003 11.840.000 -843.27%
2004 357.172.000 96.69%
2005 404.014.000 11.59%
2006 390.028.000 -3.59%
2007 417.579.000 6.6%
2008 437.031.000 4.45%
2009 537.743.000 18.73%
2010 538.056.000 0.06%
2011 218.003.000 -146.81%
2012 217.374.000 -0.29%
2013 228.162.000 4.73%
2014 240.637.000 5.18%
2015 267.836.000 10.16%
2016 301.796.000 11.25%
2017 341.542.000 11.64%
2018 378.804.000 9.84%
2019 375.172.000 -0.97%
2020 395.385.000 5.11%
2021 392.539.000 -0.73%
2022 562.331.000 30.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ypsomed Holding AG Assets
Year Assets Growth
2001 117.117.000
2002 142.962.000 18.08%
2003 500.783.000 71.45%
2004 658.482.000 23.95%
2005 665.699.000 1.08%
2006 622.789.000 -6.89%
2007 638.230.000 2.42%
2008 632.216.000 -0.95%
2009 662.010.000 4.5%
2010 674.632.000 1.87%
2011 327.273.000 -106.14%
2012 341.793.000 4.25%
2013 354.528.000 3.59%
2014 361.211.000 1.85%
2015 388.871.000 7.11%
2016 421.801.000 7.81%
2017 500.239.000 15.68%
2018 587.748.000 14.89%
2019 674.738.000 12.89%
2020 717.683.000 5.98%
2021 756.910.000 5.18%
2022 861.879.000 12.18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ypsomed Holding AG Liabilities
Year Liabilities Growth
2001 21.539.000
2002 31.279.000 31.14%
2003 488.943.000 93.6%
2004 301.310.000 -62.27%
2005 261.685.000 -15.14%
2006 232.761.000 -12.43%
2007 220.651.000 -5.49%
2008 195.185.000 -13.05%
2009 124.267.000 -57.07%
2010 136.576.000 9.01%
2011 109.270.000 -24.99%
2012 124.419.000 12.18%
2013 126.366.000 1.54%
2014 120.574.000 -4.8%
2015 121.035.000 0.38%
2016 120.005.000 -0.86%
2017 158.697.000 24.38%
2018 208.944.000 24.05%
2019 299.566.000 30.25%
2020 322.298.000 7.05%
2021 364.371.000 11.55%
2022 299.548.000 -21.64%

Ypsomed Holding AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
27.57
Net Income per Share
3.2
Price to Earning Ratio
95.5x
Price To Sales Ratio
11.09x
POCF Ratio
43.94
PFCF Ratio
178.8
Price to Book Ratio
7.4
EV to Sales
11.44
EV Over EBITDA
72.67
EV to Operating CashFlow
45.38
EV to FreeCashFlow
184.46
Earnings Yield
0.01
FreeCashFlow Yield
0.01
Market Cap
4,16 Bil.
Enterprise Value
4,30 Bil.
Graham Number
54.52
Graham NetNet
-12.05

Income Statement Metrics

Net Income per Share
3.2
Income Quality
2.17
ROE
0.07
Return On Assets
0.08
Return On Capital Employed
0.09
Net Income per EBT
0.93
EBT Per Ebit
1.36
Ebit per Revenue
0.11
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.32
Operating Profit Margin
0.11
Pretax Profit Margin
0.15
Net Profit Margin
0.14

Dividends

Dividend Yield
0
Dividend Yield %
0.21
Payout Ratio
0.09
Dividend Per Share
0.65

Operating Metrics

Operating Cashflow per Share
6.95
Free CashFlow per Share
1.71
Capex to Operating CashFlow
-0.75
Capex to Revenue
-0.19
Capex to Depreciation
-2.78
Return on Invested Capital
0.04
Return on Tangible Assets
0.07
Days Sales Outstanding
105.47
Days Payables Outstanding
26.77
Days of Inventory on Hand
78.75
Receivables Turnover
3.46
Payables Turnover
13.63
Inventory Turnover
4.64
Capex per Share
-5.24

Balance Sheet

Cash per Share
1,85
Book Value per Share
41,30
Tangible Book Value per Share
24.28
Shareholders Equity per Share
41.3
Interest Debt per Share
12.38
Debt to Equity
0.3
Debt to Assets
0.19
Net Debt to EBITDA
2.23
Current Ratio
0.8
Tangible Asset Value
0,33 Bil.
Net Current Asset Value
-0,09 Bil.
Invested Capital
0.3
Working Capital
-0,05 Bil.
Intangibles to Total Assets
0.27
Average Receivables
0,05 Bil.
Average Payables
0,02 Bil.
Average Inventory
57704000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ypsomed Holding AG Dividends
Year Dividends Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 1 100%
2017 1 0%
2018 3 50%
2019 1 -100%
2020 0 0%
2021 2 100%
2022 1 0%
2023 2 100%

Ypsomed Holding AG Profile

About Ypsomed Holding AG

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

CEO
Mr. Simon Michel
Employee
2.200
Address
Brunnmattstrasse 6
Burgdorf, 3401

Ypsomed Holding AG Executives & BODs

Ypsomed Holding AG Executives & BODs
# Name Age
1 Ms. Ulrike Bauer
Chief Business Officer of Ypsomed Delivery Systems
70
2 Mr. Sebastien Delarive
Chief Business Officer of Ypsomed Diabetes Care
70
3 Mr. Michael Zaugg
Chief Corporate Officer
70
4 Mr. Simon Michel
Member of the Board
70
5 Mr. Niklaus Ramseier
Chief Financial Officer
70
6 Mr. Frank Mengis
Chief Operating Officer
70
7 Thomas Kutt
Head of Investor Relations
70
8 Dr. Nicolas Meyer
Chief Legal Officer
70

Ypsomed Holding AG Competitors

Straumann Holding AG Logo
Straumann Holding AG

STMN.SW

(3.0)
Siegfried Holding AG Logo
Siegfried Holding AG

SFZN.SW

(2.2)
Bachem Holding AG Logo
Bachem Holding AG

BANB.SW

(2.2)
Tecan Group AG Logo
Tecan Group AG

TECN.SW

(1.8)
Comet Holding AG Logo
Comet Holding AG

COTN.SW

(3.0)